ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,575.01
-1.22%
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs Yen
155.488
0.48%
Brent Oil
83.56
0.84%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Ligand Pharmaceuticals Incorporated (LGND)

  7. Ligand Pharmaceuticals Incorporated (LGND) ニュース

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:LGND
日付受信時刻ニュースソース見出しコード企業名
2024/03/0803 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0707 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0608 : 12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0206 : 09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108 : 49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0106 : 49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2908 : 05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2907 : 43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2721 : 24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1420 : 26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1405 : 39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1309 : 42Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/1109 : 30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0607 : 40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0506 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0506 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0705 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0705 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0122 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0122 : 20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/2823 : 01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/1011 : 48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/1007 : 03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Showing the most relevant articles for your search:NASDAQ:LGND

最近閲覧した銘柄

NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
NYSE
AXP
American Express
NYSE
XOM
Exxon Mobil
FX
USDGBP
US Dollar vs Sterling
COIN
ETHUSD
Ethereum
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有